Cosmo Pharmaceuticals N.V. (SIX: COPN) announces that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a negative opinion on the marketing ...

Fortress Biotech, Inc.’s FBIO share price has dipped by 6.18%, which has investors questioning if this is right time to buy.

CABTREO, a prescription product, is a topical gel that is administered once ... the oxidizing agent benzoyl peroxide with a broad-spectrum bactericidal activity. Acne vulgaris (“vulgaris” means ...

Clascoterone cream 1% used twice daily for 2 weeks had no effect on transepidermal water loss of the skin barrier and increased facial moisturization, according to a study.“Many acne medications are ...

BHCs first-quarter 2025 adjusted earnings and revenues miss estimates. Salix performs lower than expected. Stock declines.

We have been using this product for a few weeks and have noticed ... It is a dermatologist-recommended treatment for acne vulgaris and related skin issues. Neutralyze Renewal Complex Acne ...

Sol-Gel Technologies, Ltd. has announced a product purchase agreement with ... while TWYNEO treats acne vulgaris in adults and pediatric patients. Disclaimer: This is an AI-generated summary ...

You can improve your skin texture through a combination of natural self-care methods, skincare products, and treatment options. Here are tips from a dermatologist.

In conjunction with the Reverse Split, pursuant to the amended articles of association, the par value of the Company's Ordinary Shares will be adjusted from 0.1 NIS per share to 1.0 NIS per share, and ...

Sol-Gel developed TWYNEO which is approved by the FDA for the treatment of acne vulgaris in adults and ... to complete the development of our product candidates; (iii) our ability to find ...

“This product contains either four or 10% benzoyl ... a proven treatment for mild acne vulgaris, this is a gentle, plant-powered cleanser. Tea tree oil adds antibacterial effects, and the ...

and Amzeeq for inflammatory lesions of non-nodular moderate to severe acne vulgaris. The company’s near-term revenue depends on the launch and market adoption of MROSI, which is its newly FDA ...